성병 검사 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of sexually transmitted diseases (STD) testing Market

The global sexually transmitted diseases (STD) testing market was valued at USD 11.07 billion in 2025 and is projected to grow from USD 11.97 billion in 2026 to USD 23.95 billion by 2034, registering a CAGR of 9.10% during the forecast period. The increasing prevalence of sexually transmitted infections (STIs), rising public awareness about early diagnosis, and growing government initiatives promoting routine screening are major factors supporting market expansion. North America dominated the global market with a 42.80% share in 2025, driven by advanced healthcare infrastructure, favorable reimbursement policies, and extensive awareness campaigns.

Sexually transmitted diseases remain a major public health concern worldwide. Many infections, including chlamydia, gonorrhea, syphilis, HIV, and human papillomavirus (HPV), often remain asymptomatic during the early stages, making timely testing essential for preventing transmission and ensuring effective treatment. Technological advancements in molecular diagnostics, rapid point-of-care (POC) testing, and automated laboratory systems are significantly improving testing accuracy and accessibility. Increasing investments by governments and healthcare organizations to strengthen STI screening programs are further accelerating market growth.

Rising Incidence of Sexually Transmitted Infections Driving Market Growth

The increasing number of sexually transmitted infections across both developed and developing countries is one of the strongest growth drivers for the STD testing market. According to global health organizations, millions of new infections occur annually, creating sustained demand for diagnostic kits, reagents, and laboratory instruments. Factors such as changing lifestyles, unprotected sexual practices, limited awareness in certain regions, and growing urbanization continue to contribute to the increasing disease burden.

Governments and non-profit organizations are actively promoting routine STI screening through awareness campaigns, free testing programs, and educational initiatives. Programs such as India's Suraksha Clinics and Brazil's public health initiatives have significantly improved access to testing services. These efforts are increasing testing volumes and supporting the widespread adoption of advanced diagnostic technologies worldwide.

Growing Shift toward Point-of-Care Testing Emerges as a Major Trend

One of the most significant trends shaping the STD testing market is the rapid transition from conventional laboratory-based testing to point-of-care diagnostics. Point-of-care tests provide faster results, reduce waiting times, improve treatment initiation, and minimize disease transmission. These tests are increasingly being adopted across hospitals, physician clinics, pharmacies, community health centers, and even home-based settings.

Advancements in rapid molecular diagnostics and portable testing devices are making STD testing more accessible while reducing costs. Home-based testing kits are also gaining popularity as they offer greater privacy and help overcome the social stigma associated with STI diagnosis. This growing preference for convenient and rapid testing solutions is expected to remain a major growth opportunity throughout the forecast period.

Market Challenges Include Social Stigma and Low Testing Rates

Despite significant improvements in testing technologies, reluctance toward STI testing remains a major challenge. Social stigma, confidentiality concerns, lack of sexual health awareness, and inadequate counseling services continue to discourage many individuals from seeking timely diagnosis. Certain high-risk populations also remain under-tested due to fear of discrimination and limited healthcare accessibility.

Although government awareness programs have improved testing rates, many developing regions still face shortages of trained professionals, diagnostic infrastructure, and affordable testing services. Addressing these barriers will be essential to achieving broader disease control and sustaining long-term market growth.

Chlamydia Testing and Reagents & Kits Lead Market Segments

Based on product type, the reagents & kits segment is expected to dominate the market with a 79.32% share in 2026. The increasing volume of diagnostic testing, frequent use of consumables, and continuous introduction of advanced molecular testing kits are driving segment growth.

By application, chlamydia testing is projected to account for the largest market share of 24.47% in 2026 due to its high global prevalence, increasing awareness, and availability of affordable diagnostic products. Laboratory testing will continue to dominate testing settings with a 78.33% market share in 2026, owing to its superior accuracy and widespread availability in healthcare facilities. Diagnostic centers are expected to remain the leading end-user segment, accounting for 52.34% of the global market in 2026, supported by advanced laboratory infrastructure and increasing patient preference.

North America Maintains Market Leadership while Asia Pacific Shows Strong Growth

North America generated USD 4.74 billion in 2025 and is expected to reach USD 5.14 billion in 2026, maintaining its leadership due to strong government initiatives, public-private partnerships, widespread disease awareness, and advanced diagnostic infrastructure. The U.S. continues to dominate regional demand through extensive screening programs and continuous technological innovation.

Europe remains the second-largest regional market, supported by advanced laboratory capabilities, skilled healthcare professionals, and increasing adoption of innovative testing technologies. Meanwhile, Asia Pacific is expected to witness the fastest long-term growth due to expanding healthcare infrastructure, rising government awareness campaigns, increasing STI prevalence, and improved access to affordable diagnostic services across countries such as China, India, and Japan.

Competitive Landscape

The global STD testing market remains highly competitive, with leading companies investing heavily in product innovation, strategic collaborations, geographic expansion, and research & development. Major industry participants include F. Hoffmann-La Roche Ltd., Abbott, BD, Hologic, Inc., Thermo Fisher Scientific Inc., bioMerieux, Cepheid (Danaher Corporation), Bio-Rad Laboratories, Inc., and DiaSorin S.p.A.

Recent industry developments continue to strengthen market competition. In February 2023, Roche partnered with the U.S. CDC under the Lab Networks for Health initiative to improve HIV and tuberculosis detection globally. Thermo Fisher Scientific introduced its Applied Biosystems HIV-1 Genotyping Kit, while Mylab Discovery Solutions launched rapid diagnostic kits for HIV, Hepatitis C, and Syphilis. These innovations are expanding testing capabilities and improving early disease detection worldwide.

Conclusion

The global sexually transmitted diseases testing market is positioned for strong and sustained growth through 2034, supported by increasing disease prevalence, expanding government screening initiatives, technological advancements in molecular diagnostics, and the growing adoption of rapid point-of-care testing. Although social stigma and testing reluctance continue to present challenges, ongoing investments in public health awareness, affordable diagnostic solutions, and innovative testing technologies are expected to improve early diagnosis rates. As healthcare systems increasingly prioritize preventive screening and accessible sexual health services, the STD testing market is set to play a vital role in reducing disease transmission and improving global public health.

Segmentation By Product Type, Application, Setting, End User, and Region

By Product Type * Instruments

• Reagents & Kits

By Application * Chlamydia

• Syphilis
• Genital Herpes
• Gonorrhea
• Human Immunodeficiency Virus
• Human Papillomavirus
• Others

By Setting * Laboratory Testing

• Point-of-Care

By End User * Hospital & Clinics

• Diagnostic Centers
• Others

By Region * North America (By Product Type, By Application, By Setting, By End User, By Country)

• U.S.
• Canada
• Europe (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Application, By Setting, By End User, By Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries, 2025
• 4.2. Key Industry Developments
• 4.3. Overview of Regulatory Scenario, By Key Countries/Regions
• 4.4. Technological Advancements in Sexually Transmitted Diseases Testing Market
• 4.5. Impact of COVID-19 on Global Sexually Transmitted Diseases Testing Market

5. Global Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Instruments
  • 5.1.2. Reagents & Kits
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Chlamydia
  • 5.2.2. Syphilis
  • 5.2.3. Genital Herpes
  • 5.2.4. Gonorrhea
  • 5.2.5. Human Immunodeficiency Virus
  • 5.2.6. Human Papillomavirus (HPV)
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Setting
  • 5.3.1. Laboratory Testing
  • 5.3.2. Point-of Care (POC)
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals and Clinics
  • 5.4.2. Diagnostic Centers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Instruments
  • 6.1.2. Reagents & Kits
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Chlamydia
  • 6.2.2. Syphilis
  • 6.2.3. Genital Herpes
  • 6.2.4. Gonorrhea
  • 6.2.5. Human Immunodeficiency Virus
  • 6.2.6. Human Papillomavirus (HPV)
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Setting
  • 6.3.1. Laboratory Testing
  • 6.3.2. Point-of Care (POC)
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals and Clinics
  • 6.4.2. Diagnostic Centers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Kits
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Chlamydia
  • 7.2.2. Syphilis
  • 7.2.3. Genital Herpes
  • 7.2.4. Gonorrhea
  • 7.2.5. Human Immunodeficiency Virus
  • 7.2.6. Human Papillomavirus (HPV)
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Setting
  • 7.3.1. Laboratory Testing
  • 7.3.2. Point-of Care (POC)
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals and Clinics
  • 7.4.2. Diagnostic Centers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Instruments
  • 8.1.2. Reagents & Kits
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Chlamydia
  • 8.2.2. Syphilis
  • 8.2.3. Genital Herpes
  • 8.2.4. Gonorrhea
  • 8.2.5. Human Immunodeficiency Virus
  • 8.2.6. Human Papillomavirus (HPV)
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Setting
  • 8.3.1. Laboratory Testing
  • 8.3.2. Point-of Care (POC)
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals and Clinics
  • 8.4.2. Diagnostic Centers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Instruments
  • 9.1.2. Reagents & Kits
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Chlamydia
  • 9.2.2. Syphilis
  • 9.2.3. Genital Herpes
  • 9.2.4. Gonorrhea
  • 9.2.5. Human Immunodeficiency Virus
  • 9.2.6. Human Papillomavirus (HPV)
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Setting
  • 9.3.1. Laboratory Testing
  • 9.3.2. Point-of Care (POC)
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals and Clinics
  • 9.4.2. Diagnostic Centers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Instruments
  • 10.1.2. Reagents & Kits
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Chlamydia
  • 10.2.2. Syphilis
  • 10.2.3. Genital Herpes
  • 10.2.4. Gonorrhea
  • 10.2.5. Human Immunodeficiency Virus
  • 10.2.6. Human Papillomavirus (HPV)
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Setting
  • 10.3.1. Laboratory Testing
  • 10.3.2. Point-of Care (POC)
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals and Clinics
  • 10.4.2. Diagnostic Centers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Abbott
    • 11.2.1.1. Overview,
    • 11.2.1.2. Product,
    • 11.2.1.3. SWOT Analysis,
    • 11.2.1.4. Recent Developments,
    • 11.2.1.5. Strategies,
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. F. Hoffmann-La Roche Ltd
    • 11.2.2.1. Overview,
    • 11.2.2.2. Product,
    • 11.2.2.3. SWOT Analysis,
    • 11.2.2.4. Recent Developments,
    • 11.2.2.5. Strategies,
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Becton, Dickinson and Company (BD)
    • 11.2.3.1. Overview,
    • 11.2.3.2. Product,
    • 11.2.3.3. SWOT Analysis,
    • 11.2.3.4. Recent Developments,
    • 11.2.3.5. Strategies,
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Hologic, Inc.
    • 11.2.4.1. Overview,
    • 11.2.4.2. Product,
    • 11.2.4.3. SWOT Analysis,
    • 11.2.4.4. Recent Developments,
    • 11.2.4.5. Strategies,
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Danaher Corporation
    • 11.2.5.1. Overview,
    • 11.2.5.2. Product,
    • 11.2.5.3. SWOT Analysis,
    • 11.2.5.4. Recent Developments,
    • 11.2.5.5. Strategies,
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Thermo Fisher Scientific Inc.
    • 11.2.6.1. Overview,
    • 11.2.6.2. Product,
    • 11.2.6.3. SWOT Analysis,
    • 11.2.6.4. Recent Developments,
    • 11.2.6.5. Strategies,
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. bioMerieux, Inc.
    • 11.2.7.1. Overview,
    • 11.2.7.2. Product,
    • 11.2.7.3. SWOT Analysis,
    • 11.2.7.4. Recent Developments,
    • 11.2.7.5. Strategies,
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Bio-Rad Laboratories, Inc.
    • 11.2.8.1. Overview,
    • 11.2.8.2. Product,
    • 11.2.8.3. SWOT Analysis,
    • 11.2.8.4. Recent Developments,
    • 11.2.8.5. Strategies,
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. DiaSorin Inc.
    • 11.2.9.1. Overview,
    • 11.2.9.2. Product,
    • 11.2.9.3. SWOT Analysis,
    • 11.2.9.4. Recent Developments,
    • 11.2.9.5. Strategies,
    • 11.2.9.6. financials (Based on Availability)